3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Hodgkin Disease
20
Lymphoma
6
Lymphoma, T-Cell, Peripheral
5
Lymphoma, T-Cell
5
Mycosis Fungoides
4
Lymphoma, T-Cell, Cutaneous
4
Lymphomatoid Papulosis
3
Lymphoma, Large-Cell, Anaplastic
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Lymphoma, Primary Cutaneous Anaplastic Large Cell
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Immunoblastic Lymphadenopathy
2
Hematologic Diseases
2
Enteropathy-Associated T-Cell Lymphoma
2
Squamous Cell Carcinoma of Head and Neck
1
Sezary Syndrome
1
Recurrence
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Mesothelioma, Malignant
1
Melanoma
1
Lymphoma, Extranodal NK-T-Cell
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Leukemia, Large Granular Lymphocytic
1
Leukemia
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
96
Carboplatin
67
Paclitaxel
56
Cyclophosphamide
40
Capecitabine
30
Specimen Handling
28
sacituzumab govitecan
26
130-nm albumin-bound paclitaxel
25
Gemcitabine
22
Magnetic Resonance Spectroscopy
21
olaparib
20
Doxorubicin
20
Albumin-Bound Paclitaxel
20
Taxes
19
Biopsy
19
Drug Therapy
16
atezolizumab
14
Nivolumab
14
toripalimab
12
Radiotherapy
12
Epirubicin
12
durvalumab
11
Docetaxel
10
Cisplatin
10
Bevacizumab
10
eribulin
9
fludarabine
8
Standard of Care
7
Radiation
7
Injections
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Brentuximab Vedotin
×
1 year
×
Clear all
No trials found.